Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Omeros Corp (NQ: OMER )

3.120 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9
Open 3.120
Bid (Size) 2.750 (30)
Ask (Size) 3.050 (7)
Prev. Close 3.120
Today's Range 3.120 - 3.120
52wk Range 2.500 - 18.35
Shares Outstanding 62,730,015
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
90 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) surged 70.5% to close at $0.1330 on Thursday after declining 9% on Wednesday. Allena Pharmaceuticals recently reported a $2.8 million registered... 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga

Performance

YTD
-55.19%
-55.19%
1 Month
-33.48%
-33.48%
3 Month
-54.85%
-54.85%
6 Month
-62.14%
-62.14%
1 Year
-82.46%
-82.46%

More News

Read More
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Omeros: Q1 Earnings Insights
Via Benzinga
Omeros Corporation Reports First Quarter 2022 Financial Results
From Omeros Corporation
Via Business Wire
52 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Omeros Earnings Preview
Via Benzinga
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
From Omeros Corporation
Via Business Wire
Earnings Scheduled For May 10, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
From Omeros Corporation
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Omeros's Return On Capital Employed Insights
Via Benzinga
Omeros: Q4 Earnings Insights
Via Benzinga
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
From Omeros Corporation
Via Business Wire
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
Via Benzinga
Omeros Submits Response To FDA Regarding Narsoplimab Application In HSCT-TMA
Via Benzinga
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
From Omeros Corporation
Via Business Wire
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
From Omeros Corporation
Via Business Wire
Omeros Corporation (NASDAQ:OMER) Investor Notice: Investigation over Potential Wrongdoing
Via SBWire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Omeros Corporation and Encourages Investors with Losses to Contact the Firm
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.